Anixa Biosciences Enters Development Agreement with Cytovance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy ANIX?
Anixa Biosciences announced that it has entered into a development and manufacturing agreement with Cytovance Biologics, a leading full-service contract development and manufacturing organization, or CDMO, specializing in mammalian and microbially expressed biologics, to produce cGMP clinical materials for its planned Phase 2 clinical trial of its breast cancer vaccine. The agreement follows positive final Phase 1 results in which the investigational vaccine met all primary endpoints, was safe and well tolerated at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants. Based on these results, Anixa is advancing preparations for a Phase 2 clinical trial. Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, targets alpha-lactalbumin-a lactation-associated protein that is typically expressed only in breast tissue during lactation, but which re-emerges in many forms of breast cancer. By generating an immune response against alpha-lactalbumin-expressing cells, the vaccine is designed to potentially provide both therapeutic and preventive benefits for patients with tumors expressing this protein.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANIX
Wall Street analysts forecast ANIX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.910
Low
10.00
Averages
10.00
High
10.00
Current: 2.910
Low
10.00
Averages
10.00
High
10.00
No data
About ANIX
Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anixa Biosciences Reports Positive Clinical Trial Results for Cancer Vaccines
- Breast Cancer Vaccine Progress: Anixa's breast cancer vaccine met primary endpoints in its Phase 1 clinical trial, generating protocol-defined immune responses in 74% of participants, which not only validates the vaccine's efficacy but also lays the groundwork for subsequent clinical phases, potentially accelerating market entry.
- Ovarian Cancer CAR-T Therapy: The company's ovarian cancer CAR-T therapy, lira-cel, has shown positive survival data in its ongoing Phase 1 clinical trial, a result that could enhance Anixa's competitiveness in cancer treatment and attract more investor interest in its development pipeline.
- Investor Conference Participation: Anixa's CEO, Amit Kumar, will participate in the RedChip Biotech investor conference on April 16, 2026, to discuss the company's business model and clinical advancements, providing a direct interaction opportunity with investors and boosting market confidence.
- Collaborative R&D Model: Anixa's vaccine technologies, developed in collaboration with Cleveland Clinic, focus on immunizing against
See More
Anixa Biosciences Reports Progress on Cancer Vaccine Trials
- Breast Cancer Vaccine Progress: Anixa's breast cancer vaccine met primary endpoints in its Phase 1 clinical trial, generating protocol-defined immune responses in 74% of participants, which not only demonstrates the vaccine's efficacy but also lays the groundwork for subsequent clinical phases, potentially accelerating market entry.
- Ovarian Cancer CAR-T Therapy: The ongoing Phase 1 clinical trial of Anixa's ovarian cancer CAR-T therapy, lira-cel, is showing positive survival data, which could enhance Anixa's competitiveness in cancer treatment and attract increased investor interest in its development pipeline.
- Investor Conference Participation: Anixa's CEO, Amit Kumar, will participate in the RedChip Biotech investor conference on April 16, 2026, to discuss the company's business model and clinical advancements, which not only helps raise the company's profile but also enhances interaction with investors, facilitating potential funding opportunities.
- Collaborative R&D Model: Anixa's vaccine technologies, developed in collaboration with Cleveland Clinic, focus on immunizing against
See More
Anixa Biosciences Advances Cancer Immunotherapy Pipeline
- Clinical Trial Success: Anixa's breast cancer vaccine achieved primary endpoints in its Phase 1 clinical trial, generating protocol-defined immune responses in 74% of participants, indicating significant potential for cancer prevention and enhancing the company's competitive edge in the market.
- CAR-T Therapy Progress: Anixa's ovarian cancer CAR-T therapy, lira-cel, is showing positive survival data in an ongoing Phase 1 clinical trial, highlighting the company's innovative capabilities in cancer treatment and potentially attracting increased investor interest.
- Collaborative R&D Model: The lira-cel therapy, developed in collaboration with Moffitt Cancer Center, utilizes a novel CAR-T technology where the natural ligand of the FSHR receptor binds to tumor cells, showcasing its uniqueness in cell therapy and potentially solidifying the company's leadership in biotechnology.
- Vaccine Portfolio Strategy: Anixa's collaboration with Cleveland Clinic to develop a vaccine portfolio targeting various cancers, including breast and ovarian cancer, demonstrates the company's extensive positioning in cancer immunotherapy, which may provide diversified revenue streams for future growth.
See More
Anixa Biosciences Advances Cancer Immunotherapy Pipeline
- Immunotherapy Pipeline Progress: Anixa's breast cancer vaccine achieved primary endpoints in a Phase 1 clinical trial, generating protocol-defined immune responses in 74% of participants, indicating its potential in cancer prevention and treatment, which could enhance the company's market performance.
- Positive CAR-T Data: Anixa's ovarian cancer CAR-T therapy, lira-cel, is showing positive survival data in an ongoing Phase 1 clinical trial, reflecting the company's innovative capabilities in cancer treatment and potentially attracting more investor interest.
- Collaborative Development Advantage: The lira-cel therapy, developed in collaboration with Moffitt Cancer Center, utilizes a novel CAR-T technology where the natural ligand of the FSHR receptor binds to tumor cells, showcasing its uniqueness in cell therapies and potentially providing a competitive edge for the company.
- Vaccine Combination Strategy: Anixa's collaboration with Cleveland Clinic on a vaccine portfolio targeting various intractable cancers, including breast and ovarian cancer, demonstrates the company's extensive positioning in cancer immunotherapy, which may lay the groundwork for future revenue growth.
See More
Anixa Biosciences Advances Breast Cancer Vaccine Clinical Trial Following Phase 1 Success
- Clinical Trial Success: Anixa Biosciences reported that 74% of participants in its Phase 1 clinical trial for the breast cancer vaccine generated protocol-defined immune responses, demonstrating safety and tolerability at the maximum tolerated dose, which paves the way for advancing to Phase 2 trials.
- Partnership Agreement: Anixa has entered into a development and manufacturing agreement with Cytovance Biologics to produce cGMP clinical materials for its upcoming Phase 2 trial, ensuring high-quality production for the vaccine's development.
- Innovative Vaccine Mechanism: The vaccine targets α-lactalbumin, a protein typically expressed in breast tissue that re-emerges in various breast cancers, aiming to elicit an immune response against this protein, potentially offering both therapeutic and preventive benefits for patients, highlighting its significant clinical application potential.
- Strategic Development Focus: Anixa's CEO emphasized that with positive Phase 1 data, the company is focused on advancing the vaccine program and expects to provide near-term updates on progress, demonstrating its ongoing commitment to cancer immunotherapy.
See More
Anixa Biosciences Advances Cancer Therapy with Lira-cel Trial Update
- Clinical Trial Progress: Anixa Biosciences' ongoing Phase 1 trial for ovarian cancer CAR-T therapy will be presented by principal investigator Dr. Robert Wenham at the Society of Gynecologic Oncology Annual Meeting from April 10-13, 2026, highlighting the company's commitment to advancing cancer treatment.
- Targeted Therapy Innovation: The lira-cel therapy uniquely targets the follicle-stimulating hormone receptor (FSHR), selectively expressed in ovarian cells and tumor vasculature, potentially offering new treatment options for recurrent ovarian cancer patients, thereby improving survival rates and quality of life.
- Collaborative R&D Advantage: Anixa's partnership with Moffitt Cancer Center leverages innovative CAR-T technology, showcasing the company's leadership in cancer immunotherapy while laying the groundwork for future treatment developments and enhancing market competitiveness.
- Vaccine Development Outlook: Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancers, demonstrating the company's extensive positioning across various cancer treatment areas, aiming to address multiple intractable cancers through immunotherapeutic approaches.
See More
Anixa Biosciences Reports Positive Clinical Trial Results for Cancer Vaccines
- Breast Cancer Vaccine Progress: Anixa's breast cancer vaccine met primary endpoints in its Phase 1 clinical trial, generating protocol-defined immune responses in 74% of participants, which not only validates the vaccine's efficacy but also lays the groundwork for subsequent clinical phases, potentially accelerating market entry.
- Ovarian Cancer CAR-T Therapy: The company's ovarian cancer CAR-T therapy, lira-cel, has shown positive survival data in its ongoing Phase 1 clinical trial, a result that could enhance Anixa's competitiveness in cancer treatment and attract more investor interest in its development pipeline.
- Investor Conference Participation: Anixa's CEO, Amit Kumar, will participate in the RedChip Biotech investor conference on April 16, 2026, to discuss the company's business model and clinical advancements, providing a direct interaction opportunity with investors and boosting market confidence.
- Collaborative R&D Model: Anixa's vaccine technologies, developed in collaboration with Cleveland Clinic, focus on immunizing against
See More
Anixa Biosciences Reports Progress on Cancer Vaccine Trials
- Breast Cancer Vaccine Progress: Anixa's breast cancer vaccine met primary endpoints in its Phase 1 clinical trial, generating protocol-defined immune responses in 74% of participants, which not only demonstrates the vaccine's efficacy but also lays the groundwork for subsequent clinical phases, potentially accelerating market entry.
- Ovarian Cancer CAR-T Therapy: The ongoing Phase 1 clinical trial of Anixa's ovarian cancer CAR-T therapy, lira-cel, is showing positive survival data, which could enhance Anixa's competitiveness in cancer treatment and attract increased investor interest in its development pipeline.
- Investor Conference Participation: Anixa's CEO, Amit Kumar, will participate in the RedChip Biotech investor conference on April 16, 2026, to discuss the company's business model and clinical advancements, which not only helps raise the company's profile but also enhances interaction with investors, facilitating potential funding opportunities.
- Collaborative R&D Model: Anixa's vaccine technologies, developed in collaboration with Cleveland Clinic, focus on immunizing against
See More
Anixa Biosciences Advances Cancer Immunotherapy Pipeline
- Clinical Trial Success: Anixa's breast cancer vaccine achieved primary endpoints in its Phase 1 clinical trial, generating protocol-defined immune responses in 74% of participants, indicating significant potential for cancer prevention and enhancing the company's competitive edge in the market.
- CAR-T Therapy Progress: Anixa's ovarian cancer CAR-T therapy, lira-cel, is showing positive survival data in an ongoing Phase 1 clinical trial, highlighting the company's innovative capabilities in cancer treatment and potentially attracting increased investor interest.
- Collaborative R&D Model: The lira-cel therapy, developed in collaboration with Moffitt Cancer Center, utilizes a novel CAR-T technology where the natural ligand of the FSHR receptor binds to tumor cells, showcasing its uniqueness in cell therapy and potentially solidifying the company's leadership in biotechnology.
- Vaccine Portfolio Strategy: Anixa's collaboration with Cleveland Clinic to develop a vaccine portfolio targeting various cancers, including breast and ovarian cancer, demonstrates the company's extensive positioning in cancer immunotherapy, which may provide diversified revenue streams for future growth.
See More
Anixa Biosciences Advances Cancer Immunotherapy Pipeline
- Immunotherapy Pipeline Progress: Anixa's breast cancer vaccine achieved primary endpoints in a Phase 1 clinical trial, generating protocol-defined immune responses in 74% of participants, indicating its potential in cancer prevention and treatment, which could enhance the company's market performance.
- Positive CAR-T Data: Anixa's ovarian cancer CAR-T therapy, lira-cel, is showing positive survival data in an ongoing Phase 1 clinical trial, reflecting the company's innovative capabilities in cancer treatment and potentially attracting more investor interest.
- Collaborative Development Advantage: The lira-cel therapy, developed in collaboration with Moffitt Cancer Center, utilizes a novel CAR-T technology where the natural ligand of the FSHR receptor binds to tumor cells, showcasing its uniqueness in cell therapies and potentially providing a competitive edge for the company.
- Vaccine Combination Strategy: Anixa's collaboration with Cleveland Clinic on a vaccine portfolio targeting various intractable cancers, including breast and ovarian cancer, demonstrates the company's extensive positioning in cancer immunotherapy, which may lay the groundwork for future revenue growth.
See More
Anixa Biosciences Advances Breast Cancer Vaccine Clinical Trial Following Phase 1 Success
- Clinical Trial Success: Anixa Biosciences reported that 74% of participants in its Phase 1 clinical trial for the breast cancer vaccine generated protocol-defined immune responses, demonstrating safety and tolerability at the maximum tolerated dose, which paves the way for advancing to Phase 2 trials.
- Partnership Agreement: Anixa has entered into a development and manufacturing agreement with Cytovance Biologics to produce cGMP clinical materials for its upcoming Phase 2 trial, ensuring high-quality production for the vaccine's development.
- Innovative Vaccine Mechanism: The vaccine targets α-lactalbumin, a protein typically expressed in breast tissue that re-emerges in various breast cancers, aiming to elicit an immune response against this protein, potentially offering both therapeutic and preventive benefits for patients, highlighting its significant clinical application potential.
- Strategic Development Focus: Anixa's CEO emphasized that with positive Phase 1 data, the company is focused on advancing the vaccine program and expects to provide near-term updates on progress, demonstrating its ongoing commitment to cancer immunotherapy.
See More
Anixa Biosciences Advances Cancer Therapy with Lira-cel Trial Update
- Clinical Trial Progress: Anixa Biosciences' ongoing Phase 1 trial for ovarian cancer CAR-T therapy will be presented by principal investigator Dr. Robert Wenham at the Society of Gynecologic Oncology Annual Meeting from April 10-13, 2026, highlighting the company's commitment to advancing cancer treatment.
- Targeted Therapy Innovation: The lira-cel therapy uniquely targets the follicle-stimulating hormone receptor (FSHR), selectively expressed in ovarian cells and tumor vasculature, potentially offering new treatment options for recurrent ovarian cancer patients, thereby improving survival rates and quality of life.
- Collaborative R&D Advantage: Anixa's partnership with Moffitt Cancer Center leverages innovative CAR-T technology, showcasing the company's leadership in cancer immunotherapy while laying the groundwork for future treatment developments and enhancing market competitiveness.
- Vaccine Development Outlook: Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancers, demonstrating the company's extensive positioning across various cancer treatment areas, aiming to address multiple intractable cancers through immunotherapeutic approaches.
See More
